Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Bharat's Vaccine Looks Good In New Analysis

Plus: Serum Sets India Price, RDIF Inks Korea Deal

Executive Summary

New Phase III data show efficacy ranging up to 100% for Bharat Biotech's inactivated vaccine, while also in India, Serum Institute sets new prices for its vaccine. Meanwhile, Russia's RDIF strikes new production deals in South Korea. 

You may also be interested in...



Coronavirus Update: Brazil Opens Up Vaccine Imports

Brazil is permitting imports of additional coronavirus vaccines, while in India, Serum Institute will manufacture Sputnik V, the government is unifying vaccine sourcing, and emergency use approval has been granted to Lilly's anti-COVID-19 antibodies. 

Focus On J&J, Pfizer COVID-19 Vaccine Pricing As India Permits Private Sales

Prices for J&J and Pfizer’s COVID-19 vaccines will be watched closely as India permits private sales. While demand is set to spike with age criteria for those eligible to receive the shots expanded, local manufacturers Serum Institute and Bharat Biotech are ramping up capacities with the government’s help.

Sputnik V Cleared in India, Trajectory Against Variants May Be Key

India clears Russian vaccine for restricted use, adding a third vaccine to its arsenal in the fight against COVID-19. One local expert highlights the vaccine’s “clever design” amid hopes that it will hold good against variants as well.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel